Home · Health · Sep 8 archive
Roivant Drug Hits Mid-Stage Study Goals for Pulmonary Hypertension
Developing
In Short: Roivant announced positive results from a mid-stage study of its experimental drug mosliciguat, showing a 56% reduction in pulmonary vascular resistance compared to placebo.
Roivant announced positive results from a mid-stage study of its experimental drug mosliciguat, showing a 56% reduction in pulmonary vascular resistance compared to placebo, a key measure of blood pressure and flow within the artery connecting the heart to the lungs. The drug, which could open up a new treatment approach for pulmonary hypertension, also met key secondary endpoints of the 16-week Phase 2 study with statistical significance.
According to STAT, the positive results could bolster Roivant's financial health with a second blockbuster medicine. The company stated that the drug achieved the goals of the mid-stage study, which could lead to further development and potential approval for the serious lung disease.
Roivant's announcement comes as the biotech company continues to advance its pipeline of treatments for various diseases, with this drug showing promise in treating pulmonary hypertension. The positive results from the study could pave the way for additional clinical trials and regulatory submissions.
For more details on the study and its implications, STAT+ subscribers can access the full report, which includes additional insights and analysis from industry experts.
What's confirmed
What's still developing
- To read the rest of this story subscribe to STAT+.
- You may opt out of receiving STAT communications at any time.
Sources
- STATlink